A Dose-Ranging Study of IV BNZ-1

A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL

This study is an open-label, multi-center, dose-ranging study to characterize the safety, tolerability, preliminary efficacy, and PK/PD of up to four dose levels of BNZ-1 administered weekly by IV infusion to adults diagnosed with Large Granular Lymphocyte (LGL) Leukemia or refractory Cutaneous T-cell Lymphoma (CTCL).

Website: https://www.clinicaltrials.gov/ct2/show/NCT03239392?term=bioniz

Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03239392

Contact: Paul Frohna, MD, PhD (858) 205-5285 paul@bioniz.com    

Sponsors and Collaborators
Bioniz Therapeutics


United States, Virginia
University of Virginia Cancer Center    Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Michal Ande  MMA2CZ@hscmail.mcc.virginia.edu   
Principal Investigator: Karen Ballen, MD